<DOC>
	<DOC>NCT03033069</DOC>
	<brief_summary>To evaluate the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy (Zoloft) in adults with PTSD.</brief_summary>
	<brief_title>A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder</brief_title>
	<detailed_description>This trial is designed to assess the efficacy, safety and tolerability of flexible dose brexpiprazole as monotherapy or as combination therapy with Zoloft (Sertraline) in adult subjects with PTSD. This study will consist of a continuous 12-week, double-blind treatment period with a 14-day follow-up.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders, Traumatic</mesh_term>
	<mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>Male and Female subjects between the years of 1865 with a diagnosis of PTSD (diagnosis can be made at screening) Index trauma event &gt;15 years before screening Index trauma event at age &lt;16 Any traumatic event within 3 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>